SiranBio’s Novel siRNA Drug Targeting ALK7 Grants Approval for Phase I Clinical Trial in Australia

Suzhou Siran Biotechnology Co.,Ltd. announced that its independently developed siRNA drug SA030 Injection, targeting ALK7 (Activin Receptor-Like Kinase 7), has officially received ethical approval from the Australian Human Research Ethics Committee (HREC) to proceed with a Phase I clinical trial in Australia.

Siranbio Announces Global Simultaneous IND-Related Filings for Targeted ALK7 siRNA Obesity Therapeutic SA030

Suzhou SiranBio Co., Ltd. (Siranbio) announced today that its independently developed small interfering RNA (siRNA) therapeutic candidate SA030, targeting activin receptor-like kinase 7 (ALK7), submitted a pre-IND consultation to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China on January 21, 2026. Subsequently, the Company filed an Investigational New Drug (IND) application with the Therapeutic Goods Administration (TGA) of Australia and submitted the clinical trial application to the Human Research Ethics Committee (HREC) on January 28, 2026. It also plans to submit a pre-IND meeting request to the U.S. Food and Drug Administration (FDA) in February 2026.

SiranBio Announced IND Approval for SA1211.The First Dual-Targeting siRNA Drug for CHB

[October 21, 2025, Suzhou, China] Suzhou Siran Biotechnology announces SA1211 was approved for Phase I clinical trial in China (Approval Number: 2025LP02762), for the treatment of chronic hepatitis B (CHB). SA1211 is the first dual-targeting siRNA drug which silences mRNA of HBV and PD-L1 on the infected hepatocytes. It is also the first single molecule dual-targeting siRNA that got IND approval in the world.

Dr. Zhiwei Yang Invited to University of Kentucky to Give a Seminar

The founder of SiranBio, Dr. Zhiwei Yang was invited to University of Kentucky (UK) Medical School to give a seminar titled “siRNA – How it is changing drug discovery and chronic disease treatment”.

【2024AASLD】First-in-class: Dual-Targeting siRNA for the Functional Cure of Chronic Hepatitis B, SiranBio’s SA1211 Achieved Superb Combo Treatment Results by a Single Molecule

On November 18, 2024, Dr. Zhiwei Yang, the founder of SiranBio, gave an oral presentation on the latest pre-clinical results of SA1211 in the 2024 AASLD meeting at San Diego, California. SA1211 is a dual-targeting siRNA which can activate acquired immune response in addition to directly eradicate hepatitis B virus, and thus prevent viral rebound after the end of treatment.

[2024EASL]: Siran Bio Presents Core Data on Functional Cure of Anti-PD-L1 siRNA Pipeline SA012

The 2024 Annual Meeting of the European Association for the Study of the Liver (EASL) was held in Milan, Italy, from June 5-8, 2024. Siran Bio's anti-PD-L1 siRNA pipeline, SA012, was selected for an oral poster presentation at the conference due to its impressive results. Dr. Yang Zhiwei, the founder, was invited to attend the conference and shared the details of the poster data.

Siran Bio Presents at CRT2024 Conference in the US - Sharing Research Findings on SA016, a New Antihypertensive siRNA Drug

The Cardiovascular Research Technology (CRT) Meeting 2024 was held in Washington, D.C., USA from March 9th to 12th. Siran Bio was honored to be invited to present the research findings of SA016, a new drug for treating high blood pressure, at the CRT conference. On March 10th, Dr. Yang Zhiwei, the founder of Siran Bio, shared the non-clinical efficacy and safety of SA016 in Washington, which garnered great attention and recognition from the industry.